Eli LillyLLY

關於Eli Lilly

Eli Lilly and Company is a research-driven pharmaceutical manufacturer that discovers, develops, and sells prescription medicines across a concentrated set of therapeutic areas. Its portfolio is anchored in diabetes and obesity, where incretin-based therapies built on the GLP-1 and dual GIP/GLP-1 mechanism have become the dominant revenue engine, alongside long-standing insulin franchises. Adjacent pillars include oncology, immunology, and neuroscience, with treatments spanning breast cancer, autoimmune inflammation, and Alzheimer's disease. A smaller animal-health business was separated years ago. The incretin franchise now drives the bulk of both revenue growth and operating profit, with legacy products contributing steadier but slower-growing cash flow, and the pipeline weighted heavily toward metabolic and neurodegenerative disease.

Investors track patent cliffs and loss-of-exclusivity timelines, particularly for the incretin franchise, since a handful of molecules account for a disproportionate share of profit. Manufacturing capacity for injectable peptides is another durable question, as demand has repeatedly outrun supply and Lilly has committed to a multi-year capital expenditure program to expand fill-finish and API sites. Regulatory exposure spans FDA label expansions, EMA and PMDA approvals, and U.S. drug-pricing policy including Medicare negotiation under the Inflation Reduction Act. Governance considerations include the influence of the Lilly Endowment as a large long-term shareholder, dividend continuity, and the balance between organic R&D spending, bolt-on acquisitions, and buybacks within a disciplined capital allocation framework.

The company was founded in Indianapolis in 1876 by Colonel Eli Lilly, a pharmaceutical chemist and Union Army veteran, and remains headquartered there. It rose to prominence through the commercialization of insulin in the 1920s under license from the University of Toronto, and later through Prozac in the 1980s, which reshaped psychiatric prescribing. Lilly acquired Elanco Animal Health in the 1950s and divested it via IPO and split-off completed by 2019, sharpening focus on human pharmaceuticals. Subsequent bolt-on acquisitions expanded oncology and immunology capabilities, including Loxo Oncology and Dermira. The Lilly Endowment, established in 1937 by family members, retains a substantial equity stake and reinforces long-horizon governance.

Lilly sells almost entirely to wholesalers and specialty distributors, which then supply retail pharmacies, hospitals, and integrated health systems; end demand is mediated by pharmacy benefit managers and public payers that negotiate rebates in exchange for formulary placement. Net pricing therefore diverges materially from list pricing, and gross-to-net adjustments are a core financial variable. Competitive position rests on patent-protected molecules, manufacturing scale for complex biologics and peptides, and clinical differentiation demonstrated in head-to-head trials. Its principal rivals include Novo Nordisk in metabolic disease, Merck and Bristol-Myers Squibb in oncology, and AbbVie and Johnson & Johnson in immunology. The United States generates the majority of revenue, with Europe, Japan, and China as the main international contributors.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Eli Lilly的SEC完整報告 →